TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2864997

Group type: EXPERIMENTAL
Intervention: Radiation and 5-fluorouracil
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Radiation and Adriamycin (doxorubicin)
Number of subjects: 157
Study: 31520730

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT) - 40,000 IU pancreatin, 3 times daily during meals for 3 months, n = 151
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo, n = 153
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 31236672

Group type: EXPERIMENTAL
Intervention: Topical calcipotriol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB‐UVB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined therapy (Topical calcipotriol + NB‐UVB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28642024

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (n = 38)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sham treatment (n = 37)
Number of subjects: 92
Study: 25721182

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for anxiety
Number of subjects: 66
Study: 23650882

Group type: EXPERIMENTAL
Intervention: Four-point global coherence scale
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Five-point global coherence scale
Number of subjects: 50
Study: 21477035

Group type: EXPERIMENTAL
Intervention: Whitening priming agent (Power Swabs) applied prior to whitening treatment.
Number of subjects: 25

Group type: COMPARATOR
Intervention: No whitening priming agent applied (control group).
Number of subjects: 25
Study: 18299766

Group type: EXPERIMENTAL
Intervention: IVR with feedback
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: IVR without feedback
Number of subjects: 338

Group type: COMPARATOR
Intervention: No IVR
Number of subjects: 338
Study: 16598082

Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intertransverse fusion (ITF)
Number of subjects: 20
Study: 14692438

Group type: EXPERIMENTAL
Intervention: Granisetron treatment
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 10758440

Group type: EXPERIMENTAL
Intervention: Dolasetron (12.5, 25, 50, or 100 mg)
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Dolasetron (all doses combined)
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Dolasetron (all doses)
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Dolasetron
Number of subjects: 1030
Study: 8625628

Group type: EXPERIMENTAL
Intervention: flunitrazepam/clonidine (n=54)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: chlormethiazole/haloperidol (n=50)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: flunitrazepam/haloperidol (n=55)
Number of subjects: 180
Study: 1417173

Group type: EXPERIMENTAL
Intervention: Intraportal glucose infusion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no glucose infusion)
Number of subjects: 32
Study: 3972231

Group type: EXPERIMENTAL
Intervention: Recombinant leukocyte A interferon at 36 X 10(6) U/day for 28 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recombinant leukocyte A interferon at 50 X 10(6) U/day for 28 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recombinant leukocyte A interferon at 72 X 10(6) U/day for 28 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recombinant leukocyte A interferon at 100 X 10(6) U/day for 28 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recombinant leukocyte A interferon combined with prednisolone in 5 patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Recombinant leukocyte A interferon alone in 15 patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low doses of interferon (36 and 50 X 10(6) U)
Number of subjects: 20
Study: 30823414

Group type: EXPERIMENTAL
Intervention: Probiotics (mostly a mixture of Bifidobacteria, Streptococci and Lactobacilli)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29489017

Group type: EXPERIMENTAL
Intervention: Infection prevention program involving barrier precautions, active surveillance, and NH staff education
Number of subjects: 418

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 418
Study: 26905278

Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Number of subjects: 4247

Group type: COMPARATOR
Intervention: Sulfadoxine-Pyrimethamine (SP)
Number of subjects: 4247
Study: 24522489

Group type: EXPERIMENTAL
Intervention: Micro-percutaneous nephrolithotomy (microperc)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional percutaneous nephrolithotomy (PNL)
Number of subjects: 20
Study: 22364685

Group type: EXPERIMENTAL
Intervention: Defibrotide prophylaxis
Number of subjects: 356

Group type: COMPARATOR
Intervention: Control (no defibrotide)
Number of subjects: 356
Study: 20503801

Group type: EXPERIMENTAL
Intervention: Auditory steady-state responses (ASSRs) for complex toneburst stimuli
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Speech feature discrimination (SFD) abilities
Number of subjects: 17
Study: 17668530

Group type: EXPERIMENTAL
Intervention: Combined therapy of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and topical metronidazole gel 1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical metronidazole gel 1%
Number of subjects: 0
Study: 15383192

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day + statin
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Ezetimibe + statin
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Ezetimibe + statin (DM subgroup)
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Ezetimibe + statin (MetS subgroup)
Number of subjects: 769

Group type: COMPARATOR
Intervention: Placebo + statin
Number of subjects: 769
Study: 11385890

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxanes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study: 9208336

Group type: EXPERIMENTAL
Intervention: Spirapril
Number of subjects: 37

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 37
Study: 8272249

Group type: EXPERIMENTAL
Intervention: Filtral
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: F 60
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All dialysers
Number of subjects: 0
Study: 3541997

Group type: EXPERIMENTAL
Intervention: Intravenous timolol
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 31005676

Group type: EXPERIMENTAL
Intervention: Parent Participation Improvement Program for parents in neonatal intensive care units (2 weeks duration)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine visits (Control group)
Number of subjects: 66
Study: 27825891

Group type: EXPERIMENTAL
Intervention: 3-month recall period
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: 6-month recall period
Number of subjects: 432

Group type: COMPARATOR
Intervention: Comparison between 3-month and 6-month recall periods
Number of subjects: 432
Study: 26894175

Group type: EXPERIMENTAL
Intervention: Topical 0.2% hyaluronic acid therapy for 14 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Topical placebo application for 14 days
Number of subjects: 50
Study: 24424513

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Number of subjects: 589

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 589
Study: 22536936

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) for 16 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Attention-control (AC)
Number of subjects: 66
Study: 18973518

Group type: EXPERIMENTAL
Intervention: Phytate-containing mouthwash (20 mL, twice daily for 1 min)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control mouthwash
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 25
Study: 17577007

Group type: EXPERIMENTAL
Intervention: Study treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo or other treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 16342649

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg orally) from the start of DVd-T treatment (group 1)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg orally) after the start of DVd-T treatment (group 2)
Number of subjects: 105

Group type: COMPARATOR
Intervention: No aspirin (group 3)
Number of subjects: 105
Study: 11991271

Group type: COMPARATOR
Intervention: Sodium tetradecyl sulfate (STS) at 0.25%, 0.5%, or 1.5% depending on vein size
Number of subjects: 129

Group type: COMPARATOR
Intervention: Polidocanol (POL) at 0.5%, 1.0%, or 3% depending on vein size
Number of subjects: 129
Study: 10330634

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% gel
Number of subjects: 25

Group type: COMPARATOR
Intervention: Tetracaine 0.5% drops
Number of subjects: 25
Study: 8950968

Group type: EXPERIMENTAL
Intervention: Metallic stents placed percutaneous-transhepatically
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Metallic stents
Number of subjects: 65
Study: 1900094

Group type: EXPERIMENTAL
Intervention: Danazol (200 mg/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Naloxone (1.6 mg/h x 4 h preceded by 1.6 mg iv bolus)
Number of subjects: 6
Study: 7128220

Group type: EXPERIMENTAL
Intervention: Theophylline (low dose: 8.7-13.0 micrograms/ml)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Theophylline (high dose: 16.0-23.6 micrograms/ml)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30409023

Group type: EXPERIMENTAL
Intervention: 6% hypertonic saline (HS) inhalation, twice daily for 52 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0.9% isotonic saline (IS) inhalation, twice daily for 52 weeks
Number of subjects: 42
Study: 28008093

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytics (alteplase)
Number of subjects: 300
Study: 25656349

Group type: EXPERIMENTAL
Intervention: LR-based education group (context of Low LR model)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: State Of The Art (SOTA) education group (without emphasis on LR)
Number of subjects: 454

Group type: COMPARATOR
Intervention: No-intervention Control Group
Number of subjects: 454
Study: 23219965

Group type: EXPERIMENTAL
Intervention: 10 Hz tACS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 20 Hz tACS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study: 21157261

Group type: EXPERIMENTAL
Intervention: Advancing Research and Clinical practice through close Collaboration (ARCC) model
Number of subjects: 46

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 46
Study: 19824382

Group type: EXPERIMENTAL
Intervention: Prostamol-UNO 320 mg/day for 36 months
Number of subjects: 0
Study: 17145264

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg orally 2-3 hours before MRCP
Number of subjects: 35
Study: 15561257

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cyclosporine Neoral (CsA)
Number of subjects: 26
Study: 11584850

Group type: EXPERIMENTAL
Intervention: 0.4% hypotonic hyaluronic acid (HHA) eye drops
Number of subjects: 135

Group type: COMPARATOR
Intervention: 0.3% hydroxypropylmethylcellulose plus 0.1% Dextran 70 (HPMC) eye drops
Number of subjects: 135
Study: 8731664

Group type: EXPERIMENTAL
Intervention: 0.05% all-trans retinoic acid (RA) in ethanol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.1% all-trans retinoic acid (RA) in ethanol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% sodium lauryl sulphate (SLS) in water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RA followed by SLS in tandem design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SLS followed by RA in tandem design
Number of subjects: 0
Study: 1303409

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 200
Study: 3904434

Group type: EXPERIMENTAL
Intervention: Isoxicam 200 mg once daily
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Isoxicam (long-term phase)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 3612496

Group type: EXPERIMENTAL
Intervention: Lignocaine HCl 120 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MEGX HCl 120 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lignocaine HCl 120 mg + MEGX HCl 120 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30172038

Group type: EXPERIMENTAL
Intervention: Hypertension personal control program (HPCP) with home blood pressure monitoring
Number of subjects: 350

Group type: COMPARATOR
Intervention: Home blood pressure monitoring alone
Number of subjects: 350
Study: 28982109

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 342

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 342
Study: 25767371

Group type: EXPERIMENTAL
Intervention: Lobeglitazone (0.5 mg) with warfarin (25 mg) on day 5
Number of subjects: 24

Group type: COMPARATOR
Intervention: Warfarin (25 mg) alone
Number of subjects: 24
Study: 23067366

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day for 12 months
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no celecoxib)
Number of subjects: 140
Study: 20004274

Group type: EXPERIMENTAL
Intervention: Conventional regimen (21+7 days)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Extended-cycle regimen (84+7 days)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control cycle (baseline)
Number of subjects: 59
Study: 20666297

Group type: EXPERIMENTAL
Intervention: Care managers linking patients to primary care after psychiatric crisis
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Qualitative inquiry
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Primary care services
Number of subjects: 85
Study: 16608035

Group type: EXPERIMENTAL
Intervention: Intraoperative adjuvant therapy (hepatectomy plus microwave coagulonecrotic therapy or radiofrequency ablation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Postoperative adjuvant therapy (transcatheter arterial embolization)
Number of subjects: 30
Study: 12667969

Group type: EXPERIMENTAL
Intervention: Acupuncture (real needles)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (placebo needles)
Number of subjects: 22
Study: 10752876

Group type: EXPERIMENTAL
Intervention: Map projection CT colonography (Mercator projection)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Map projection CT colonography (Stereographic projection)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional CT colonography (VC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Viewing axial slices
Number of subjects: 9
Study: 9375593

Group type: EXPERIMENTAL
Intervention: Pimozide treatment for 6 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1547677

Group type: EXPERIMENTAL
Intervention: Diabeto (computer‐assisted diet education system)
Number of subjects: 105
Study: 3890521

Group type: EXPERIMENTAL
Intervention: Oral glucose-electrolyte solution with 60 mEq/L sodium and 2% glucose
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral glucose-electrolyte solution with 30 mEq/L sodium and 5% glucose
Number of subjects: 60
Study: 30221485

Group type: EXPERIMENTAL
Intervention: MTX-TNFi
Number of subjects: 2296

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 2296
Study: 30143730

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Inactive children
Number of subjects: 362
Study: 27638896

Group type: EXPERIMENTAL
Intervention: Hysteroscopically guided biopsy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Blind biopsy
Number of subjects: 82
Study: 25238506

Group type: EXPERIMENTAL
Intervention: Homeopathic complex (Atropa belladonna D4, Calcarea phosphoricum D4, Hepar sulphuris D4, Kalium bichromat D4, Kalium muriaticum D4, Mercurius protoiodid D10, and Mercurius biniodid D10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (unmedicated vehicle)
Number of subjects: 30
Study: 23734933

Group type: EXPERIMENTAL
Intervention: Telaprevir-based triple therapy (T12/PR24 group)
Number of subjects: 267

Group type: COMPARATOR
Intervention: PEG‐IFN‐α‐2b and RBV for 48 weeks (PR48 group)
Number of subjects: 267
Study: 20484150

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (0.6 mg/kg i.v. bolus)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18467727

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily
Number of subjects: 731

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731
Study: 16648064

Group type: EXPERIMENTAL
Intervention: Rate Smoothing On (RS On)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Rate Smoothing Off (RS Off)
Number of subjects: 569
Study: 12859220

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 0
Study: 10866897

Group type: EXPERIMENTAL
Intervention: Remifentanil-N(2)O
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane-N(2)O-fentanyl
Number of subjects: 60
Study: 9187778

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 0.25%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural bupivacaine 0.25%
Number of subjects: 60
Study: 1389703

Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography
Number of subjects: 131

Group type: COMPARATOR
Intervention: Precordial echocardiography
Number of subjects: 131

Group type: COMPARATOR
Intervention: Clinical detection
Number of subjects: 131
Study: 3516407

Group type: EXPERIMENTAL
Intervention: Glycinated aspirin swallowed without water (600 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Soluble aspirin swallowed with water (600 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both treatments (Glycinated aspirin and Soluble aspirin)
Number of subjects: 16
Study: 30768404

Group type: EXPERIMENTAL
Intervention: Sleep extension (9.5 hours)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sleep restriction (6.5 hours)
Number of subjects: 72
Study: 29496036

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus cetuximab
Number of subjects: 68

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 68
Study: 26613823

Group type: EXPERIMENTAL
Intervention: 30 μg ethinyl estradiol (EE) with 3mg drospirenone
Number of subjects: 112

Group type: COMPARATOR
Intervention: 20 μg ethinyl estradiol (EE) with 3mg drospirenone
Number of subjects: 112
Study: 26573461

Group type: EXPERIMENTAL
Intervention: School-located vaccination against influenza (SLV-I)
Number of subjects: 18410

Group type: EXPERIMENTAL
Intervention: Cost-per-vaccinated child excluding vaccine purchase
Number of subjects: 18410

Group type: EXPERIMENTAL
Intervention: Indirect costs of SLV-I
Number of subjects: 18410

Group type: COMPARATOR
Intervention: Standard-of-care (no SLV-I)
Number of subjects: 18410
Study: 23160038

Group type: EXPERIMENTAL
Intervention: Test tooth (dehydrated)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control tooth (not dehydrated)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Panel assessment of test and control teeth
Number of subjects: 20
Study: 19844185

Group type: EXPERIMENTAL
Intervention: Hypertensive group
Number of subjects: 1720

Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 1720
Study: 18216044

Group type: EXPERIMENTAL
Intervention: School-based influenza immunization program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidemiologically based influenza immunization policy
Number of subjects: 0
Study: 15985589

Group type: EXPERIMENTAL
Intervention: Early withdrawal of antiepileptic drugs
Number of subjects: 0
Study: 12857695

Group type: EXPERIMENTAL
Intervention: 13-hour longitudinal residents-as-teachers curriculum
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 10543667

Group type: EXPERIMENTAL
Intervention: Nitrendipine 5 mg twice daily
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg twice daily
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo (normotensive)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo (hypertensive)
Number of subjects: 253
Study: 8677941

Group type: EXPERIMENTAL
Intervention: Interferon therapy (natural alpha-interferon, 6 MU daily for 2 weeks, then 3 times a week for 22 weeks)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Interferon therapy (natural alpha-interferon, 6 MU daily for 8 weeks, then 2 times a week for 12 weeks)
Number of subjects: 63
Study: 1723446

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 22
Study: 7337197

Group type: EXPERIMENTAL
Intervention: 15% relative humidity (RH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50% relative humidity (RH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 85% relative humidity (RH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dry air
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Humid air
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50% relative humidity (RH) for both tests
Number of subjects: 0
Study: 29993146

Group type: EXPERIMENTAL
Intervention: PDT (ALA 20% incubated 1.5 hours before red light irradiation with 37 J/cm2 fluence)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Doxycycline 100 mg/d plus adapalene gel 0.1%
Number of subjects: 46
Study: 28012272

Group type: EXPERIMENTAL
Intervention: PBAC score at 12 months follow-up
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Change in PBAC score
Number of subjects: 900
Study: 25201350

Group type: EXPERIMENTAL
Intervention: Patsari stove
Number of subjects: 668

Group type: COMPARATOR
Intervention: Traditional wood fire
Number of subjects: 668
Study: 23456498

Group type: EXPERIMENTAL
Intervention: Shudh™ colon cleanse (SCC)
Number of subjects: 133

Group type: COMPARATOR
Intervention: HalfLytely(®) colon prep (HCP)
Number of subjects: 133